| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 25.035 | 56.104 | 141.046 | 159.623 | 217.588 | 293.899 |
| Total Income - EUR | - | - | - | - | 25.035 | 56.104 | 141.046 | 159.623 | 217.588 | 294.515 |
| Total Expenses - EUR | - | - | - | - | 15.884 | 47.519 | 120.893 | 144.107 | 210.887 | 290.058 |
| Gross Profit/Loss - EUR | - | - | - | - | 9.151 | 8.586 | 20.153 | 15.516 | 6.701 | 4.457 |
| Net Profit/Loss - EUR | - | - | - | - | 8.900 | 8.065 | 18.912 | 13.999 | 4.850 | -3.409 |
| Employees | - | - | - | - | 2 | 1 | 2 | 2 | 3 | 4 |
Check the financial reports for the company - Syrodent By Dr. Adel Abboud S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 1.317 | 13.613 | 60.455 | 72.784 | 86.926 | 137.253 |
| Current Assets | - | - | - | - | 9.949 | 19.244 | 21.980 | 14.926 | 21.110 | 24.043 |
| Inventories | - | - | - | - | 10 | 9.641 | 3.665 | 5.738 | 7.221 | 2.409 |
| Receivables | - | - | - | - | 87 | 1.199 | 4.225 | 1.231 | 1.803 | 5.796 |
| Cash | - | - | - | - | 9.852 | 8.404 | 14.090 | 7.957 | 12.086 | 15.838 |
| Shareholders Funds | - | - | - | - | 8.942 | 16.838 | 35.377 | 49.486 | 54.186 | 50.474 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 2.324 | 16.035 | 47.130 | 38.224 | 53.850 | 110.823 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8623 - 8623" | |||||||||
| CAEN Financial Year |
8623
|
|||||||||
Comments - Syrodent By Dr. Adel Abboud S.r.l.